Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK329 is an effective and selective inhibitor of TNNI3 Interacting Kinase (TNNI3K). GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 396.00 | |
25 mg | In stock | $ 663.00 | |
50 mg | In stock | $ 945.00 | |
100 mg | In stock | $ 1,280.00 | |
500 mg | In stock | $ 2,570.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 288.00 |
Description | GSK329 is an effective and selective inhibitor of TNNI3 Interacting Kinase (TNNI3K). GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury. |
Synonyms | GSK 329, GSK-329 |
Molecular Weight | 472.25 |
Formula | C19H14Cl2F3N5O2 |
CAS No. | 1268490-12-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 245 mg/mL (518.79 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK329 1268490-12-5 Others GSK 329 diarylurea cardiac-specific kinase cardioprotective outcomes inhibit Inhibitor ischemia/reperfusion GSK-329 TNNI3K inhibitor